患者来源的异种移植瘤（PDXs）是通过将人类肿瘤移植到小鼠体内生成的。可连续移植的PDXs可用于研究肿瘤生物学和测试治疗方法，将实验室与临床联系起来。尽管大型储库中只有少数前列腺癌PDXs可用，但已建立了330多个前列腺癌PDXs，涵盖了广泛的临床阶段、基因型和表型。然而，需要更多的PDXs来反映患者的多样性，并研究新的治疗和新兴的抗拒机制。我们可以通过交换模型和数据集，将PDXs存入生物储库，最大程度地利用PDXs，但我们必须解决访问PDXs的障碍，例如机构、伦理和法律协议。通过合作，研究人员将获得更广泛的前列腺癌特征的PDXs的访问权。© 2023. Springer Nature Limited.

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although few prostate cancer PDXs are available in large repositories, over 330 prostate cancer PDXs have been established, spanning broad clinical stages, genotypes and phenotypes. Nevertheless, more PDXs are needed to reflect patient diversity, and to study new treatments and emerging mechanisms of resistance. We can maximize the use of PDXs by exchanging models and datasets, and by depositing PDXs into biorepositories, but we must address the impediments to accessing PDXs, such as institutional, ethical and legal agreements. Through collaboration, researchers will gain greater access to PDXs representing diverse features of prostate cancer.© 2023. Springer Nature Limited.